<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39460899</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0267</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Clinical reviews in allergy &amp; immunology</Title><ISOAbbreviation>Clin Rev Allergy Immunol</ISOAbbreviation></Journal><ArticleTitle>MDA5 Is a Major Determinant of Developing Symptoms in Critically Ill COVID-19 Patients.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12016-024-09008-z</ELocationID><Abstract><AbstractText>Apart from the skin and mucosal immune barrier, the first line of defense of the human immune system includes MDA5 (ifih1 gene) which acts as a cellular sensor protein for certain viruses including SARS-CoV-2. Upon binding with viral RNA, MDA5 activates cell-intrinsic innate immunity, humoral responses, and MAVS (mitochondrial antiviral signaling). MAVS signaling induces type I and III interferon (IFN) expressions that further induce ISGs (interferon stimulatory genes) expressions to initiate human cell-mediated immune responses and attenuate viral replication. SARS-CoV-2 counteracts by producing NSP1, NSP2, NSP3, NSP5, NSP7, NSP12, ORF3A, ORF9, N, and M protein and directs anti-MDA5 antibody production presumably to antagonize IFN signaling. Furthermore, COVID-19 resembles several diseases that carry anti-MDA5 antibodies and the current COVID-19 vaccines induced anti-MDA5 phenotypes in healthy individuals. GWAS (genome-wide association studies) identified several polymorphisms (SNPs) in the ifih1-ifn pathway genes including rs1990760 in ifih1 that are strongly associated with COVID-19, and the associated risk allele is correlated with reduced IFN production. The genetic association of SNPs in ifih1 and ifih1-ifn pathway genes reinforces the molecular findings of the critical roles of MDA5 in sensing SARS-CoV-2 and subsequently the IFN responses to inhibit viral replication and host immune evasion. Thus, MDA5 or its pathway genes could be targeted for therapeutic development of COVID-19.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maiti</LastName><ForeName>Amit K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Mydnavar, Department of Genetics and Genomics, 28475 Greenfield Rd, Southfield, MI, USA. akmit123@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Rev Allergy Immunol</MedlineTA><NlmUniqueID>9504368</NlmUniqueID><ISSNLinking>1080-0549</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ifih1</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Gene therapy</Keyword><Keyword MajorTopicYN="N">MDA5</Keyword><Keyword MajorTopicYN="N">Polymorphisms</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Virus sensor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>11</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460899</ArticleId><ArticleId IdType="doi">10.1007/s12016-024-09008-z</ArticleId><ArticleId IdType="pii">10.1007/s12016-024-09008-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Greenhalgh T et al (2021) Ten scientific reasons in support of airbourne transmission of SARS-CoV2. The Lancet 397(10285):1603–1605</Citation></Reference><Reference><Citation>Zhou P et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273</Citation><ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId><ArticleId IdType="pmc">7095418</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler CGK et al (2020) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181(5):1016-1035.e19</Citation><ArticleIdList><ArticleId IdType="pubmed">32413319</ArticleId><ArticleId IdType="pmc">7252096</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.04.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone B et al (2022) Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat Rev Mol Cell Biol 23(1):21–39</Citation><ArticleIdList><ArticleId IdType="pubmed">34824452</ArticleId><ArticleId IdType="doi">10.1038/s41580-021-00432-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271–280</Citation><ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId><ArticleId IdType="pmc">7102627</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Eymieux S et al (2021) Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release. Cell Mol Life Sci 78(7):3565–3576</Citation><ArticleIdList><ArticleId IdType="pubmed">33449149</ArticleId><ArticleId IdType="pmc">7809227</ArticleId><ArticleId IdType="doi">10.1007/s00018-020-03745-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Vkovski P et al (2021) Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 19(3):155–170</Citation><ArticleIdList><ArticleId IdType="pubmed">33116300</ArticleId><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S et al (2020) SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct Target Ther 5(1):235</Citation><ArticleIdList><ArticleId IdType="pubmed">33037188</ArticleId><ArticleId IdType="pmc">7545816</ArticleId><ArticleId IdType="doi">10.1038/s41392-020-00334-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JF et al (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395(10223):514–523</Citation><ArticleIdList><ArticleId IdType="pubmed">31986261</ArticleId><ArticleId IdType="pmc">7159286</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30154-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D et al (2020) Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181(5):1036-1045.e9</Citation><ArticleIdList><ArticleId IdType="pubmed">32416070</ArticleId><ArticleId IdType="pmc">7227586</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C et al (2020) Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584(7821):463–469</Citation><ArticleIdList><ArticleId IdType="pubmed">32717743</ArticleId><ArticleId IdType="pmc">7477538</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YM, Shin EC (2021) Type I and III interferon responses in SARS-CoV-2 infection. Exp Mol Med 53(5):750–760</Citation><ArticleIdList><ArticleId IdType="pubmed">33953323</ArticleId><ArticleId IdType="pmc">8099704</ArticleId><ArticleId IdType="doi">10.1038/s12276-021-00592-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y et al (2021) SARS-CoV-2 Nsp5 demonstrates two distinct mechanisms targeting RIG-I and MAVS to evade the innate immune response. mBio 12(5):e0233521</Citation><ArticleIdList><ArticleId IdType="pubmed">34544279</ArticleId><ArticleId IdType="doi">10.1128/mBio.02335-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G et al (2021) ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. Nat Microbiol 6(4):467–478</Citation><ArticleIdList><ArticleId IdType="pubmed">33727702</ArticleId><ArticleId IdType="pmc">8103894</ArticleId><ArticleId IdType="doi">10.1038/s41564-021-00884-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T et al (2010) LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc Natl Acad Sci U S A 107(4):1512–1517</Citation><ArticleIdList><ArticleId IdType="pubmed">20080593</ArticleId><ArticleId IdType="pmc">2824407</ArticleId><ArticleId IdType="doi">10.1073/pnas.0912986107</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber G (2017) The molecular basis for differential type I interferon signaling. J Biol Chem 292(18):7285–7294</Citation><ArticleIdList><ArticleId IdType="pubmed">28289098</ArticleId><ArticleId IdType="pmc">5418031</ArticleId><ArticleId IdType="doi">10.1074/jbc.R116.774562</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou JH et al (2018) Type III interferons in viral infection and antiviral immunity. Cell Physiol Biochem 51(1):173–185</Citation><ArticleIdList><ArticleId IdType="pubmed">30439714</ArticleId><ArticleId IdType="doi">10.1159/000495172</ArticleId></ArticleIdList></Reference><Reference><Citation>Odendall C, Kagan JC (2015) The unique regulation and functions of type III interferons in antiviral immunity. Curr Opin Virol 12:47–52</Citation><ArticleIdList><ArticleId IdType="pubmed">25771505</ArticleId><ArticleId IdType="pmc">4470718</ArticleId><ArticleId IdType="doi">10.1016/j.coviro.2015.02.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wack A, Terczyńska-Dyla E, Hartmann R (2015) Guarding the frontiers: the biology of type III interferons. Nat Immunol 16(8):802–809</Citation><ArticleIdList><ArticleId IdType="pubmed">26194286</ArticleId><ArticleId IdType="pmc">7096991</ArticleId><ArticleId IdType="doi">10.1038/ni.3212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AJ, Ashkar AA (2018) The dual nature of type I and type II interferons. Front Immunol 9:2061</Citation><ArticleIdList><ArticleId IdType="pubmed">30254639</ArticleId><ArticleId IdType="pmc">6141705</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.02061</ArticleId></ArticleIdList></Reference><Reference><Citation>Negishi H et al (2008) A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci U S A 105(51):20446–20451</Citation><ArticleIdList><ArticleId IdType="pubmed">19074283</ArticleId><ArticleId IdType="pmc">2629334</ArticleId><ArticleId IdType="doi">10.1073/pnas.0810372105</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercammen E, Staal J, Beyaert R (2008) Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin Microbiol Rev 21(1):13–25</Citation><ArticleIdList><ArticleId IdType="pubmed">18202435</ArticleId><ArticleId IdType="pmc">2223843</ArticleId><ArticleId IdType="doi">10.1128/CMR.00022-07</ArticleId></ArticleIdList></Reference><Reference><Citation>Lester SN, Li K (2014) Toll-like receptors in antiviral innate immunity. J Mol Biol 426(6):1246–1264</Citation><ArticleIdList><ArticleId IdType="pubmed">24316048</ArticleId><ArticleId IdType="doi">10.1016/j.jmb.2013.11.024</ArticleId></ArticleIdList></Reference><Reference><Citation>Moresco EM, Beutler B (2010) LGP2: positive about viral sensing. Proc Natl Acad Sci U S A 107(4):1261–1262</Citation><ArticleIdList><ArticleId IdType="pubmed">20133887</ArticleId><ArticleId IdType="pmc">2824419</ArticleId><ArticleId IdType="doi">10.1073/pnas.0914011107</ArticleId></ArticleIdList></Reference><Reference><Citation>Maarouf M et al (2018) Immune ecosystem of virus-infected host tissues. Int J Mol Sci 19(5):1379</Citation><ArticleIdList><ArticleId IdType="pubmed">29734779</ArticleId><ArticleId IdType="pmc">5983771</ArticleId><ArticleId IdType="doi">10.3390/ijms19051379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehwinkel J, Gack MU (2020) RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol 20(9):537–551</Citation><ArticleIdList><ArticleId IdType="pubmed">32203325</ArticleId><ArticleId IdType="pmc">7094958</ArticleId><ArticleId IdType="doi">10.1038/s41577-020-0288-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoagland DA et al (2021) Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity 54(3):557-570.e5</Citation><ArticleIdList><ArticleId IdType="pubmed">33577760</ArticleId><ArticleId IdType="pmc">7846242</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2021.01.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova JL, Anderson MS (2023) Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs. J Clin Invest 133(3):e166283</Citation></Reference><Reference><Citation>Park A, Iwasaki A (2020) Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe 27(6):870–878</Citation><ArticleIdList><ArticleId IdType="pubmed">32464097</ArticleId><ArticleId IdType="pmc">7255347</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2020.05.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370(6515):eabd4585</Citation><ArticleIdList><ArticleId IdType="pubmed">32972996</ArticleId><ArticleId IdType="pmc">7857397</ArticleId><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi D et al (2024) Prevalence of neutralizing autoantibodies against type I interferon in a multicenter cohort of severe or critical COVID-19 cases in Shanghai. J Clin Immunol 44(3):80</Citation><ArticleIdList><ArticleId IdType="pubmed">38462559</ArticleId><ArticleId IdType="pmc">10925575</ArticleId><ArticleId IdType="doi">10.1007/s10875-024-01683-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G et al (2021) Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front Immunol 12:791348</Citation><ArticleIdList><ArticleId IdType="pubmed">34987516</ArticleId><ArticleId IdType="pmc">8720853</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.791348</ArticleId></ArticleIdList></Reference><Reference><Citation>Barral PM et al (2009) Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity. Pharmacol Ther 124(2):219–234</Citation><ArticleIdList><ArticleId IdType="pubmed">19615405</ArticleId><ArticleId IdType="pmc">3165056</ArticleId><ArticleId IdType="doi">10.1016/j.pharmthera.2009.06.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo YM et al (2008) Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol 82(1):335–345</Citation><ArticleIdList><ArticleId IdType="pubmed">17942531</ArticleId><ArticleId IdType="doi">10.1128/JVI.01080-07</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Olagnier D, Lin R (2016) Host and viral modulation of RIG-I-mediated antiviral immunity. Front Immunol 7:662</Citation><ArticleIdList><ArticleId IdType="pubmed">28096803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H et al (2008) Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205(7):1601–1610</Citation><ArticleIdList><ArticleId IdType="pubmed">18591409</ArticleId><ArticleId IdType="pmc">2442638</ArticleId><ArticleId IdType="doi">10.1084/jem.20080091</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampaio NG et al (2021) The RNA sensor MDA5 detects SARS-CoV-2 infection. Sci Rep 11(1):13638</Citation><ArticleIdList><ArticleId IdType="pubmed">34211037</ArticleId><ArticleId IdType="pmc">8249624</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-92940-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Belgnaoui SM, Paz S, Hiscott J (2011) Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. Curr Opin Immunol 23(5):564–572</Citation><ArticleIdList><ArticleId IdType="pubmed">21865020</ArticleId><ArticleId IdType="doi">10.1016/j.coi.2011.08.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Molineros JE et al (2013) Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet 9(2):e1003222</Citation><ArticleIdList><ArticleId IdType="pubmed">23441136</ArticleId><ArticleId IdType="pmc">3575474</ArticleId><ArticleId IdType="doi">10.1371/journal.pgen.1003222</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Bae S, Myoung J (2019) Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design. J Microbiol 57(9):803–811</Citation><ArticleIdList><ArticleId IdType="pubmed">31452044</ArticleId><ArticleId IdType="pmc">7091237</ArticleId><ArticleId IdType="doi">10.1007/s12275-019-9272-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemeyer D et al (2013) Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol 87(22):12489–12495</Citation><ArticleIdList><ArticleId IdType="pubmed">24027320</ArticleId><ArticleId IdType="pmc">3807936</ArticleId><ArticleId IdType="doi">10.1128/JVI.01845-13</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiti AK (2020) The African-American population with a low allele frequency of SNP rs1990760 (T allele) in IFIH1 predicts less IFN-beta expression and potential vulnerability to COVID-19 infection. Immunogenetics 72(6):387–391</Citation><ArticleIdList><ArticleId IdType="pubmed">32737579</ArticleId><ArticleId IdType="pmc">7394703</ArticleId><ArticleId IdType="doi">10.1007/s00251-020-01174-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorne LG et al (2021) SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. EMBO J 40(15):e107826</Citation><ArticleIdList><ArticleId IdType="pubmed">34101213</ArticleId><ArticleId IdType="pmc">8209947</ArticleId><ArticleId IdType="doi">10.15252/embj.2021107826</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M et al (2022) SARS-CoV-2 modulation of RIG-I-MAVS signaling: potential mechanisms of impairment on host antiviral immunity and therapeutic approaches. MedComm Futur Med 1(2):e29</Citation><ArticleIdList><ArticleId IdType="pubmed">37521851</ArticleId><ArticleId IdType="pmc">9878249</ArticleId><ArticleId IdType="doi">10.1002/mef2.29</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano T et al (2021) X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol 6(62):eabl4348</Citation><ArticleIdList><ArticleId IdType="pubmed">34413140</ArticleId><ArticleId IdType="pmc">8532080</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.abl4348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q et al (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370(6515):eabd4570</Citation><ArticleIdList><ArticleId IdType="pubmed">32972995</ArticleId><ArticleId IdType="pmc">7857407</ArticleId><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X et al (2021) MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep 34(2):108628</Citation><ArticleIdList><ArticleId IdType="pubmed">33440148</ArticleId><ArticleId IdType="pmc">7832566</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.108628</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebendenne A et al (2021) SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells. J Virol 95(8):10–1128</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02415-20</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn RA et al (2021) Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions. Cell 184(9):2394-2411.e16</Citation><ArticleIdList><ArticleId IdType="pubmed">33743211</ArticleId><ArticleId IdType="pmc">7951565</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.03.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J et al (2021) Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection. Cell 184(1):76-91.e13</Citation><ArticleIdList><ArticleId IdType="pubmed">33147444</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.10.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Asgari S et al (2017) Severe viral respiratory infections in children with. Proc Natl Acad Sci U S A 114(31):8342–8347</Citation><ArticleIdList><ArticleId IdType="pubmed">28716935</ArticleId><ArticleId IdType="pmc">5547624</ArticleId><ArticleId IdType="doi">10.1073/pnas.1704259114</ArticleId></ArticleIdList></Reference><Reference><Citation>Loske J et al (2022) Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat Biotechnol 40(3):319–324</Citation><ArticleIdList><ArticleId IdType="pubmed">34408314</ArticleId><ArticleId IdType="doi">10.1038/s41587-021-01037-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Wummers H et al (2023) Multi-omics analysis of mucosal and systemic immunity to SARS-XCoV2 after Birth. Cell 186:4632–4651</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.08.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon AK, Hollander GA, McMichael A (1821) Evolution of the immune system in humans from infancy to old age. Proc Biol Sci 2015(282):20143085</Citation></Reference><Reference><Citation>Du Y et al (2018) LRRC25 inhibits type I IFN signaling by targeting ISG15-associated RIG-I for autophagic degradation. EMBO J 37(3):351–366</Citation><ArticleIdList><ArticleId IdType="pubmed">29288164</ArticleId><ArticleId IdType="doi">10.15252/embj.201796781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Zhang DE (2011) Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res 31(1):119–130</Citation><ArticleIdList><ArticleId IdType="pubmed">21190487</ArticleId><ArticleId IdType="pmc">3021351</ArticleId><ArticleId IdType="doi">10.1089/jir.2010.0110</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemm T et al (2020) Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO J 39(18):e106275</Citation><ArticleIdList><ArticleId IdType="pubmed">32845033</ArticleId><ArticleId IdType="pmc">7461020</ArticleId><ArticleId IdType="doi">10.15252/embj.2020106275</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddicoat BJ et al (2015) RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science 349(6252):1115–1120</Citation><ArticleIdList><ArticleId IdType="pubmed">26275108</ArticleId><ArticleId IdType="pmc">5444807</ArticleId><ArticleId IdType="doi">10.1126/science.aac7049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourier T et al (2021) Host-directed editing of the SARS-CoV-2 genome. Biochem Biophys Res Commun 538:35–39</Citation><ArticleIdList><ArticleId IdType="pubmed">33234239</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2020.10.092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratcliff J, Simmonds P (2021) Potential APOBEC-mediated RNA editing of the genomes of SARS-CoV-2 and other coronaviruses and its impact on their longer term evolution. Virology 556:62–72</Citation><ArticleIdList><ArticleId IdType="pubmed">33545556</ArticleId><ArticleId IdType="doi">10.1016/j.virol.2020.12.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillon MC et al (2021) Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight into nuclease specificity and dynamics. Nat Commun 12(1):636</Citation><ArticleIdList><ArticleId IdType="pubmed">33504779</ArticleId><ArticleId IdType="pmc">7840905</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-20608-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier MN et al (2022) Flipped over U: structural basis for dsRNA cleavage by the SARS-CoV-2 endoribonuclease. Nucleic Acids Res 50(14):8290–8301</Citation><ArticleIdList><ArticleId IdType="pubmed">35801916</ArticleId><ArticleId IdType="pmc">9371922</ArticleId><ArticleId IdType="doi">10.1093/nar/gkac589</ArticleId></ArticleIdList></Reference><Reference><Citation>Azgari C et al (2021) The mutation profile of SARS-CoV-2 is primarily shaped by the host antiviral defense. Viruses 13(3):394</Citation><ArticleIdList><ArticleId IdType="pubmed">33801257</ArticleId><ArticleId IdType="pmc">7999997</ArticleId><ArticleId IdType="doi">10.3390/v13030394</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung C et al (2022) Omicron: what makes the latest SARS-CoV-2 variant of concern so concerning? J Virol 96(6):e0207721</Citation><ArticleIdList><ArticleId IdType="pubmed">35225672</ArticleId><ArticleId IdType="doi">10.1128/jvi.02077-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH et al (2022) Interferon antagonists encoded by SARS-CoV-2 at a glance. Med Microbiol Immunol 212(2):125–131</Citation><ArticleIdList><ArticleId IdType="pubmed">35366686</ArticleId><ArticleId IdType="pmc">8976456</ArticleId><ArticleId IdType="doi">10.1007/s00430-022-00734-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoms M et al (2020) Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science 369(6508):1249–1255</Citation><ArticleIdList><ArticleId IdType="pubmed">32680882</ArticleId><ArticleId IdType="pmc">7402621</ArticleId><ArticleId IdType="doi">10.1126/science.abc8665</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S et al (2021) Coronavirus Nsp1: immune response suppression and protein expression inhibition. Front Microbiol 12:752214</Citation><ArticleIdList><ArticleId IdType="pubmed">34659188</ArticleId><ArticleId IdType="pmc">8512706</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2021.752214</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z et al (2022) SARS-CoV-2 impairs interferon production via NSP2-induced repression of mRNA translation. Proc Natl Acad Sci U S A 119(32):e2204539119</Citation><ArticleIdList><ArticleId IdType="pubmed">35878012</ArticleId><ArticleId IdType="pmc">9371684</ArticleId><ArticleId IdType="doi">10.1073/pnas.2204539119</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H et al (2020) Evasion of type I interferon by SARS-CoV-2. Cell Rep 33(1):108234</Citation><ArticleIdList><ArticleId IdType="pubmed">32979938</ArticleId><ArticleId IdType="pmc">7501843</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.108234</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui C et al (2022) SARS-CoV-2 NSP13 inhibits type I IFN production by degradation of TBK1 via p62-dependent selective autophagy. J Immunol 208(3):753–761</Citation><ArticleIdList><ArticleId IdType="pubmed">34996837</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.2100684</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen CK et al (2020) SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect 9(1):1418–1428</Citation><ArticleIdList><ArticleId IdType="pubmed">32529952</ArticleId><ArticleId IdType="pmc">7473193</ArticleId><ArticleId IdType="doi">10.1080/22221751.2020.1780953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayn M et al (2021) Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities. Cell Rep 35(7):109126</Citation><ArticleIdList><ArticleId IdType="pubmed">33974846</ArticleId><ArticleId IdType="pmc">8078906</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.109126</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu JC et al (2021) Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Proc Natl Acad Sci U S A 118(24):e2101161118</Citation><ArticleIdList><ArticleId IdType="pubmed">34045361</ArticleId><ArticleId IdType="pmc">8214666</ArticleId><ArticleId IdType="doi">10.1073/pnas.2101161118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W et al (2021) SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Cell Mol Immunol 18(4):945–953</Citation><ArticleIdList><ArticleId IdType="pubmed">33637958</ArticleId><ArticleId IdType="doi">10.1038/s41423-020-00619-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ A et al (2022) Nsp16 shields SARS-CoV-2 from efficient MDA5 sensing and IFIT1-mediated restriction. EMBO Rep 23(12):e55648</Citation><ArticleIdList><ArticleId IdType="pubmed">36285486</ArticleId><ArticleId IdType="pmc">9724656</ArticleId><ArticleId IdType="doi">10.15252/embr.202255648</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R et al (2021) ORF3a protein of severe acute respiratory syndrome coronavirus 2 inhibits interferon-activated Janus kinase/signal transducer and activator of transcription signaling. Front Microbiol 12:752597</Citation><ArticleIdList><ArticleId IdType="pubmed">34650546</ArticleId><ArticleId IdType="pmc">8506155</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2021.752597</ArticleId></ArticleIdList></Reference><Reference><Citation>Miorin L et al (2020) SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci U S A 117(45):28344–28354</Citation><ArticleIdList><ArticleId IdType="pubmed">33097660</ArticleId><ArticleId IdType="pmc">7668094</ArticleId><ArticleId IdType="doi">10.1073/pnas.2016650117</ArticleId></ArticleIdList></Reference><Reference><Citation>García-García T et al (2022) Impairment of antiviral immune response and disruption of cellular functions by SARS-CoV-2 ORF7a and ORF7b. iScience 25(11):105444</Citation><ArticleIdList><ArticleId IdType="pubmed">36310646</ArticleId><ArticleId IdType="pmc">9597514</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2022.105444</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui L et al (2021) SARS-CoV-2 membrane protein inhibits type I interferon production through ubiquitin-mediated degradation of TBK1. Front Immunol 12:662989</Citation><ArticleIdList><ArticleId IdType="pubmed">34084167</ArticleId><ArticleId IdType="pmc">8168463</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.662989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HH et al (2018) Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3. Virology 515:165–175</Citation><ArticleIdList><ArticleId IdType="pubmed">29294448</ArticleId><ArticleId IdType="doi">10.1016/j.virol.2017.12.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Han L et al (2021) SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways. J Med Virol 93(9):5376–5389</Citation><ArticleIdList><ArticleId IdType="pubmed">33913550</ArticleId><ArticleId IdType="pmc">8242602</ArticleId><ArticleId IdType="doi">10.1002/jmv.27050</ArticleId></ArticleIdList></Reference><Reference><Citation>Nombel A, Fabien N, Coutant F (2021) Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol 12:773352</Citation><ArticleIdList><ArticleId IdType="pubmed">34745149</ArticleId><ArticleId IdType="pmc">8564476</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.773352</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderle K et al (2022) COVID-19 as a putative trigger of anti-MDA5-associated dermatomyositis with acute respiratory distress syndrome (ARDS) requiring lung transplantation, a case report. BMC Rheumatol 6(1):42</Citation><ArticleIdList><ArticleId IdType="pubmed">35821079</ArticleId><ArticleId IdType="pmc">9277832</ArticleId><ArticleId IdType="doi">10.1186/s41927-022-00271-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura M, Sugimoto H (2021) Clinically amyopathic dermatomyositis during the COVID-19 pandemic. Oxf Med Case Rep 2021(8):omab061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/omcr/omab061</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Noumi B, Malik F (2023) A rare case of MDA-5-positive amyopathic dermatomyositis with rapidly progressive interstitial lung disease following COVID-19 mRNA vaccination - a case report. SN Compr Clin Med 5(1):18</Citation><ArticleIdList><ArticleId IdType="pubmed">36530960</ArticleId><ArticleId IdType="doi">10.1007/s42399-022-01357-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo Y et al (2021) COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still’s disease. Clin Exp Rheumatol 39(3):631–638</Citation><ArticleIdList><ArticleId IdType="pubmed">33886458</ArticleId><ArticleId IdType="doi">10.55563/clinexprheumatol/44kaji</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q (2020) MDA5 should be detected in severe COVID-19 patients. Med Hypotheses 143:109890</Citation><ArticleIdList><ArticleId IdType="pubmed">32485313</ArticleId><ArticleId IdType="pmc">7832998</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2020.109890</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannini M et al (2020) Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J 56(3):2001618</Citation></Reference><Reference><Citation>Cavagna L et al (2023) Idiopathic inflammatory myopathies and COVID-19: an intriguing liaison? Clin Exp Rheumatol 41(2):217–220</Citation><ArticleIdList><ArticleId IdType="pubmed">36826807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharouf F et al (2023) Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience. Clin Exp Rheumatol 41(2):316–321</Citation><ArticleIdList><ArticleId IdType="pubmed">36826786</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshtkarjahromi M et al (2021) Macrophage activation syndrome in MDA5 antibody-positive dermatomyositis and COVID-19 infection. BMC Rheumatol 5(1):59</Citation><ArticleIdList><ArticleId IdType="pubmed">34895325</ArticleId><ArticleId IdType="pmc">8666190</ArticleId><ArticleId IdType="doi">10.1186/s41927-021-00225-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X et al (2020) Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 117(20):10970–10975</Citation><ArticleIdList><ArticleId IdType="pubmed">32350134</ArticleId><ArticleId IdType="pmc">7245089</ArticleId><ArticleId IdType="doi">10.1073/pnas.2005615117</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez D et al (2022) Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. Rheumatol Int 42(9):1629–1641</Citation><ArticleIdList><ArticleId IdType="pubmed">35661906</ArticleId><ArticleId IdType="pmc">9166182</ArticleId><ArticleId IdType="doi">10.1007/s00296-022-05149-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Woddard V, Mann B (2023) A case of COVID vaccine associated anti-MDA5 antibody dermatomyositis. Chest 164:A3327–A3328</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2023.07.2173</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S et al (2022) A case of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung diseases developed after administration of COVID-19 vaccine and subsequent pneumococcal vaccine. Respirol Case Rep 10(12):e01064</Citation><ArticleIdList><ArticleId IdType="pubmed">36348741</ArticleId><ArticleId IdType="pmc">9630759</ArticleId><ArticleId IdType="doi">10.1002/rcr2.1064</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L et al (2023) A case of Anti-MDA5-Positive dermatomyositis after inactivated COVID-19 vaccine. J Eur Acad Dermatol Venereol 37(2):e127–e129</Citation><ArticleIdList><ArticleId IdType="pubmed">36222733</ArticleId><ArticleId IdType="doi">10.1111/jdv.18653</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer MT et al (2022) New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol Int 42(12):2267–2276</Citation><ArticleIdList><ArticleId IdType="pubmed">35939078</ArticleId><ArticleId IdType="pmc">9358381</ArticleId><ArticleId IdType="doi">10.1007/s00296-022-05176-3</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Bravo L et al (2022) Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies. J Transl Autoimmun 5:100160</Citation><ArticleIdList><ArticleId IdType="pubmed">35789569</ArticleId><ArticleId IdType="pmc">9242685</ArticleId><ArticleId IdType="doi">10.1016/j.jtauto.2022.100160</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouda W et al (2022) Dermatomyositis following BNT162b2 mRNA COVID-19 vaccination. J Korean Med Sci 37(5):e32</Citation><ArticleIdList><ArticleId IdType="pubmed">35132838</ArticleId><ArticleId IdType="pmc">8822116</ArticleId><ArticleId IdType="doi">10.3346/jkms.2022.37.e32</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitajima T et al (2022) Antimelanoma differentiation-associated gene 5 antibody-positive interstitial lung disease after vaccination with COVID-19 mRNA vaccines. J Rheumatol 49(10):1158–1162</Citation><ArticleIdList><ArticleId IdType="pubmed">35705246</ArticleId><ArticleId IdType="doi">10.3899/jrheum.220259</ArticleId></ArticleIdList></Reference><Reference><Citation>Nejentsev S et al (2009) Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 324(5925):387–389</Citation><ArticleIdList><ArticleId IdType="pubmed">19264985</ArticleId><ArticleId IdType="pmc">2707798</ArticleId><ArticleId IdType="doi">10.1126/science.1167728</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y et al (2012) Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 44(6):676–680</Citation><ArticleIdList><ArticleId IdType="pubmed">22561518</ArticleId><ArticleId IdType="pmc">3366044</ArticleId><ArticleId IdType="doi">10.1038/ng.2272</ArticleId></ArticleIdList></Reference><Reference><Citation>Baechler EC et al (2006) Gene expression profiling in human autoimmunity. Immunol Rev 210:120–137</Citation><ArticleIdList><ArticleId IdType="pubmed">16623768</ArticleId><ArticleId IdType="doi">10.1111/j.0105-2896.2006.00367.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman JA et al (2017) The A946T variant of the RNA sensor IFIH1 mediates an interferon program that limits viral infection but increases the risk for autoimmunity. Nat Immunol 18(7):744–752</Citation><ArticleIdList><ArticleId IdType="pubmed">28553952</ArticleId><ArticleId IdType="pmc">5697900</ArticleId><ArticleId IdType="doi">10.1038/ni.3766</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregersen PK, Olsson LM (2009) Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 27:363–391</Citation><ArticleIdList><ArticleId IdType="pubmed">19302045</ArticleId><ArticleId IdType="pmc">2992886</ArticleId><ArticleId IdType="doi">10.1146/annurev.immunol.021908.132653</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli M et al (2010) Population genetics of IFIH1: ancient population structure, local selection, and implications for susceptibility to type 1 diabetes. Mol Biol Evol 27(11):2555–2566</Citation><ArticleIdList><ArticleId IdType="pubmed">20538742</ArticleId><ArticleId IdType="doi">10.1093/molbev/msq141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sironi M, Clerici M (2010) The hygiene hypothesis: an evolutionary perspective. Microbes Infect 12(6):421–427</Citation><ArticleIdList><ArticleId IdType="pubmed">20178858</ArticleId><ArticleId IdType="doi">10.1016/j.micinf.2010.02.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Muñiz-Banciella MG et al (2022) Age-dependent effect of the IFIH1/MDA5 gene variants on the risk of critical COVID-19. Immunogenetics 75(2):91–98</Citation><ArticleIdList><ArticleId IdType="pubmed">36434151</ArticleId><ArticleId IdType="pmc">9702716</ArticleId><ArticleId IdType="doi">10.1007/s00251-022-01281-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado-Rodríguez L et al (2022) Effects of IFIH1 rs1990760 variants on systemic inflammation and outcome in critically ill COVID-19 patients in an observational translational study. Elife 11:e73012</Citation><ArticleIdList><ArticleId IdType="pubmed">35060899</ArticleId><ArticleId IdType="pmc">8782569</ArticleId><ArticleId IdType="doi">10.7554/eLife.73012</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieter C et al (2022) Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: a systematic review and meta-analysis. PLoS ONE 17(7):e0270627</Citation><ArticleIdList><ArticleId IdType="pubmed">35793369</ArticleId><ArticleId IdType="pmc">9258831</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0270627</ArticleId></ArticleIdList></Reference><Reference><Citation>Initiative CHG (2021) Mapping the human genetic architecture of COVID-19. Nature 600:472–477</Citation></Reference><Reference><Citation>Pairo-Castineira E et al (2021) Genetic mechanisms of critical illness in COVID-19. Nature 591(7848):92–98</Citation><ArticleIdList><ArticleId IdType="pubmed">33307546</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-03065-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmiedel BJ et al (2021) COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types. Nat Commun 12(1):6760</Citation><ArticleIdList><ArticleId IdType="pubmed">34799557</ArticleId><ArticleId IdType="pmc">8604964</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-26888-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabihi Rizi F et al (2023) TYK2 single-nucleotide variants associated with the severity of COVID-19 disease. Arch Virol 168(4):119</Citation><ArticleIdList><ArticleId IdType="pubmed">36959416</ArticleId><ArticleId IdType="pmc">10035968</ArticleId><ArticleId IdType="doi">10.1007/s00705-023-05729-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink-Baldauf IM et al (2022) CRISPRi links COVID-19 GWAS loci to LZTFL1 and RAVER1. EBioMedicine 75:103806</Citation><ArticleIdList><ArticleId IdType="pubmed">34998241</ArticleId><ArticleId IdType="pmc">8731227</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2021.103806</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor AF et al (2023) Human genome polymorphisms and computational intelligence approach revealed a complex genomic signature for COVID-19 severity in Brazilian patients. Viruses 15(3):645</Citation><ArticleIdList><ArticleId IdType="pubmed">36992353</ArticleId><ArticleId IdType="pmc">10059592</ArticleId><ArticleId IdType="doi">10.3390/v15030645</ArticleId></ArticleIdList></Reference><Reference><Citation>Velavan TP et al (2021) Host genetic factors determining COVID-19 susceptibility and severity. EBioMedicine 72:103629</Citation><ArticleIdList><ArticleId IdType="pubmed">34655949</ArticleId><ArticleId IdType="pmc">8512556</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2021.103629</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez J et al (2021) The Interferon-induced transmembrane protein 3 gene (IFITM3) rs12252 C variant is associated with COVID-19. Cytokine 137:155354</Citation><ArticleIdList><ArticleId IdType="pubmed">33113474</ArticleId><ArticleId IdType="doi">10.1016/j.cyto.2020.155354</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B et al (2020) Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182(4):812-827.e19</Citation><ArticleIdList><ArticleId IdType="pubmed">32697968</ArticleId><ArticleId IdType="pmc">7332439</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.06.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiti AK (2022) Evolutionary shift from purifying selection towards divergent selection of SARS-CoV2 favors its invasion into multiple human organs. Virus Res 313:198712</Citation><ArticleIdList><ArticleId IdType="pubmed">35176330</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2022.198712</ArticleId></ArticleIdList></Reference><Reference><Citation>Andolfo I et al (2021) Common variants at 21q22.3 locus influence. iScience 24(4):102322</Citation><ArticleIdList><ArticleId IdType="pubmed">33748697</ArticleId><ArticleId IdType="pmc">7968217</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2021.102322</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidari Nia M et al (2022) Association of polymorphisms in tumor necrosis factors with SARS-CoV-2 infection and mortality rate: a case-control study and in silico analyses. J Med Virol 94(4):1502–1512</Citation><ArticleIdList><ArticleId IdType="pubmed">34821383</ArticleId><ArticleId IdType="doi">10.1002/jmv.27477</ArticleId></ArticleIdList></Reference><Reference><Citation>Banday AR et al (2022) Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. Nat Genet 54(8):1103–1116</Citation><ArticleIdList><ArticleId IdType="pubmed">35835913</ArticleId><ArticleId IdType="pmc">9355882</ArticleId><ArticleId IdType="doi">10.1038/s41588-022-01113-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J et al (2021) The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2. Gene 768:145325</Citation><ArticleIdList><ArticleId IdType="pubmed">33253796</ArticleId><ArticleId IdType="doi">10.1016/j.gene.2020.145325</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama T et al (2020) An aberrant STAT pathway is central to COVID-19. Cell Death Differ 27(12):3209–3225</Citation><ArticleIdList><ArticleId IdType="pubmed">33037393</ArticleId><ArticleId IdType="doi">10.1038/s41418-020-00633-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Long SW et al (2020) Molecular architecture of early dissemination and massive second wave of the SARS-CoV-2 virus in a major metropolitan area. mBio 11(6):10–1128</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02707-20</ArticleId></ArticleIdList></Reference><Reference><Citation>Danziger O et al (2022) Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2 restriction factor. PLoS Pathog 18(4):e1010464</Citation><ArticleIdList><ArticleId IdType="pubmed">35421191</ArticleId><ArticleId IdType="pmc">9041830</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1010464</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadler AJ, Williams BR (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8(7):559–568</Citation><ArticleIdList><ArticleId IdType="pubmed">18575461</ArticleId><ArticleId IdType="pmc">2522268</ArticleId><ArticleId IdType="doi">10.1038/nri2314</ArticleId></ArticleIdList></Reference><Reference><Citation>Montenegro AFL, Clementino MAF, Yaochite JNU (2024) Type I interferon pathway genetic variants in severe COVID-19. Virus Res 342:199339</Citation><ArticleIdList><ArticleId IdType="pubmed">38354910</ArticleId><ArticleId IdType="pmc">10901847</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2024.199339</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H et al (2013) RAVER1 is a coactivator of MDA5-mediated cellular antiviral response. J Mol Cell Biol 5(2):111–119</Citation><ArticleIdList><ArticleId IdType="pubmed">23390309</ArticleId><ArticleId IdType="doi">10.1093/jmcb/mjt006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IF et al (2020) Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395(10238):1695–1704</Citation><ArticleIdList><ArticleId IdType="pubmed">32401715</ArticleId><ArticleId IdType="pmc">7211500</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)31042-4</ArticleId></ArticleIdList></Reference><Reference><Citation>To KK et al (2020) Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 20(5):565–574</Citation><ArticleIdList><ArticleId IdType="pubmed">32213337</ArticleId><ArticleId IdType="pmc">7158907</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(20)30196-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q et al (2020) Life-threatening COVID-19: defective interferons unleash excessive inflammation. Med 1(1):14–20</Citation><ArticleIdList><ArticleId IdType="pubmed">33363283</ArticleId><ArticleId IdType="doi">10.1016/j.medj.2020.12.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinschek B et al (2015) Interferon-beta therapy of multiple sclerosis patients improves the responsiveness of T cells for immune suppression by regulatory T cells. Int J Mol Sci 16(7):16330–16346</Citation><ArticleIdList><ArticleId IdType="pubmed">26193267</ArticleId><ArticleId IdType="pmc">4519953</ArticleId><ArticleId IdType="doi">10.3390/ijms160716330</ArticleId></ArticleIdList></Reference><Reference><Citation>Monk PD et al (2021) Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 9(2):196–206</Citation><ArticleIdList><ArticleId IdType="pubmed">33189161</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(20)30511-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC et al (2021) Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med 9(12):1365–1376</Citation><ArticleIdList><ArticleId IdType="pubmed">34672949</ArticleId><ArticleId IdType="pmc">8523116</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(21)00384-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamir H et al (2022) Induction of innate immune response by TLR3 agonist protects mice against SARS-CoV-2 infection. Viruses 14(2):189</Citation><ArticleIdList><ArticleId IdType="pubmed">35215785</ArticleId><ArticleId IdType="pmc">8878863</ArticleId><ArticleId IdType="doi">10.3390/v14020189</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin R et al (2022) The intersection molecule MDA5 in cancer and COVID-19. Front Immunol 13:963051</Citation><ArticleIdList><ArticleId IdType="pubmed">36119095</ArticleId><ArticleId IdType="pmc">9471860</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.963051</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo K et al (2022) Interferon resistance of emerging SARS-CoV-2 variants. Proc Natl Acad Sci U S A 119(32):e2203760119</Citation><ArticleIdList><ArticleId IdType="pubmed">35867811</ArticleId><ArticleId IdType="pmc">9371743</ArticleId><ArticleId IdType="doi">10.1073/pnas.2203760119</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiti AK (2023) Therapeutic challenges in COVID-19. Curr Mol Med 24:14–25</Citation></Reference><Reference><Citation>Maiti AK (2022) Omics approaches in COVID-19: an overview. In: Barh D, De Car Azevedo VA (eds) Omics approaches and technologies in COVID-19. Elsevier Publications, Amsterdam, pp 3–21</Citation></Reference><Reference><Citation>Brosey CA et al (2021) Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors. Prog Biophys Mol Biol 163:171–186</Citation><ArticleIdList><ArticleId IdType="pubmed">33636189</ArticleId><ArticleId IdType="pmc">7901392</ArticleId><ArticleId IdType="doi">10.1016/j.pbiomolbio.2021.02.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil C et al (2020) COVID-19: drug targets and potential treatments. J Med Chem 63(21):12359–12386</Citation><ArticleIdList><ArticleId IdType="pubmed">32511912</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.0c00606</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>